| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/20/2002 | EP1188057A2 Incorporation and appliations of biomolecular interactions within a carrier |
| 03/20/2002 | EP1187932A2 Mammalian toll homologues and uses thereof |
| 03/20/2002 | EP1187931A1 49 human secreted proteins |
| 03/20/2002 | EP1187927A2 Hcv/bvdv chimeric genomes and uses thereof |
| 03/20/2002 | EP1187924A1 Substrate trapping protein tyrosine phosphatases |
| 03/20/2002 | EP1187923A1 Apoptosis inhibition by adenovirus e3/6.7k |
| 03/20/2002 | EP1187919A2 Recombinant adenoviruses for the sodium/iodide symporter (nis) |
| 03/20/2002 | EP1187918A1 Tek antagonists |
| 03/20/2002 | EP1187917A1 Cd44 splice variant associated with rheumatoid arthritis |
| 03/20/2002 | EP1187916A2 Identification and molecular characterisation of proteins, expressed in the tick salivary glands |
| 03/20/2002 | EP1187915A2 Compounds for therapy and diagnosis of lung cancer and methods for their use |
| 03/20/2002 | EP1187913A1 Screening method for peptides |
| 03/20/2002 | EP1187911A2 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
| 03/20/2002 | EP1187908A1 42 human secreted proteins |
| 03/20/2002 | EP1187852A1 EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS |
| 03/20/2002 | EP1187851A1 Novel integrin alpha subunit and uses thereof |
| 03/20/2002 | EP1187850A1 Antimicrobial theta defensins and methods of using same |
| 03/20/2002 | EP1187849A1 Meth1 and meth2 polynucleotides and polypeptides |
| 03/20/2002 | EP1187848A1 Annexin derivatives with endogenous chelation sites |
| 03/20/2002 | EP1187847A1 Streptogramin derivatives, preparation and compositions containing them |
| 03/20/2002 | EP1187844A1 Human carbamyl phosphate synthetase i polymorphism and diagnostic and therapeutic methods relating thereto |
| 03/20/2002 | EP1187843A1 Angiogenic proteins and uses thereof |
| 03/20/2002 | EP1187842A1 Human tumor necrosis factor receptor tr10 |
| 03/20/2002 | EP1187639A1 Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| 03/20/2002 | EP1187636A1 Injectable hyaluronate-sulfated polysaccharide conjugates |
| 03/20/2002 | EP1187634A1 Cell growth inhibition |
| 03/20/2002 | EP1187628A2 Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| 03/20/2002 | EP1187627A2 Uses of h-trek-1 polypeptides and polynucleotides encoding them |
| 03/20/2002 | EP1187626A1 Methods for producing 5'-nucleic acid-protein conjugates |
| 03/20/2002 | EP1187625A1 Structure-based design of compounds that inhibit detrimental cytotoxic t lymphocyte responses |
| 03/20/2002 | EP1187624A1 Conformationally constrained backbone cyclized interleukin-6 antagonists |
| 03/20/2002 | EP1187623A1 Prevention of post surgical adhesions using a fibrin monomer sealant |
| 03/20/2002 | EP1187622A1 Method of sterilizing |
| 03/20/2002 | EP1187620A1 Antisense modulation of b7 protein expression |
| 03/20/2002 | EP1187619A1 Anti-tumor agents comprising boroproline compounds |
| 03/20/2002 | EP1187615A2 Immunosurpressive effects of pteridine derivatives |
| 03/20/2002 | EP1187591A2 Ibd-associated microbial antigens and methods of using same |
| 03/20/2002 | EP0800829B1 Antitumor agent potentiator comprising il-6 antagonist |
| 03/20/2002 | EP0785796B1 A pharmaceutical formulation comprising a growth hormone and isoleucine |
| 03/20/2002 | EP0777680B1 Urokinase receptor ligands |
| 03/20/2002 | EP0672421B1 Endothelin activity inhibitor |
| 03/20/2002 | EP0642351B1 New pharmaceutical uses of krill enzymes |
| 03/20/2002 | EP0610475B1 Nerve-derived transglutaminase enzyme useful for inducing nerve regeneration |
| 03/20/2002 | EP0593501B1 Biocidal proteins |
| 03/20/2002 | EP0591385B1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 03/20/2002 | EP0589961B1 Assay systems for neurotrophin activity |
| 03/20/2002 | EP0418316B1 Platelet-specific chimeric immunoglobulin |
| 03/20/2002 | CN1341124A Anti-CD3 immunotoxins and therapeutic use thereof |
| 03/20/2002 | CN1341122A Covalently bridged insulin dimers |
| 03/20/2002 | CN1341121A Expression and export of anti-obesity proteins as Fc fusion proteins |
| 03/20/2002 | CN1341120A 骨刺激因子 Bone stimulator |
| 03/20/2002 | CN1341119A Melanocyte-stimulating hormone inhibitors |
| 03/20/2002 | CN1341028A New use of melagatran |
| 03/20/2002 | CN1341027A Inhibitors for use in hemostasis and immune function |
| 03/20/2002 | CN1341026A Small peptides and methods for treatment of asthma and inflammation |
| 03/20/2002 | CN1340629A Method for using human CRYGS gene and its coded products to diagnose and treat lesion of crystalline lens |
| 03/20/2002 | CN1340624A Polypeptide-human cathepsin 10.12 and polynucleotide for coding it |
| 03/20/2002 | CN1340623A Polypeptide-glycosyl hydrolase 33.55 and polynucleotide for coding it |
| 03/20/2002 | CN1340622A Polypeptide-serine/threonine protein kinase MO1511.11 and polynucleotide for coding it |
| 03/20/2002 | CN1340621A Polypeptide-human casein kinase II alpha subunit 22.44 and polynucleotide for coding it |
| 03/20/2002 | CN1340620A Polypeptide-human phosphoryl choline/ethanolamine transferase 22.99 and polynucleotide for coding it |
| 03/20/2002 | CN1340619A Polypeptide-hydrogenase 9.13 and polynucleotide for coding it |
| 03/20/2002 | CN1340618A Polypeptide-nucleotide reductase 13.31 and polynucleotide for coding it |
| 03/20/2002 | CN1340617A Polypeptide-phosphoribosyl glycinamide synthetase 26.39 and polynucleotide for coding it |
| 03/20/2002 | CN1340616A Polypeptide-human fructose-6-phosphate, 2-kinase/fructose-2,6-diphosphatase 14.08 and polynucleotide for coding it |
| 03/20/2002 | CN1340615A Polypeptide-human uracil mononucleotide synthetase 42.79 and polynucleotide for coding it |
| 03/20/2002 | CN1340358A Long-acting intra-ocular release system of cyclosporin |
| 03/20/2002 | CN1081187C Inhibitors of prenuyl transferases |
| 03/20/2002 | CN1081041C Medicine for treatment of malignant tumour and its prepn |
| 03/19/2002 | USRE37596 Hybridoma cell line which produces the monoclonal antibody bw sclc-1 having the deposit number ecacc no. 90022110. |
| 03/19/2002 | US6359194 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 03/19/2002 | US6359193 Nucleotide sequences of lats genes |
| 03/19/2002 | US6359182 C-nitroso compounds and use thereof |
| 03/19/2002 | US6359158 A 16-hydroxyeicosatetraenoic acid antagonist; antiinflammatory agents |
| 03/19/2002 | US6359127 Oligonucleotide for use in treatment of cancer and nervous system disorders |
| 03/19/2002 | US6359126 Antibodies to αvβ3 integrin |
| 03/19/2002 | US6359123 H-rev107-like protein |
| 03/19/2002 | US6359116 Compounds |
| 03/19/2002 | US6359112 Peptides used as agonists and/or inhibitors of amyloid formation and cytotoxicity and also for use in alzheimer's disease, in type II diabetes mellitus and in spongiform encephalophathies |
| 03/19/2002 | US6359003 Fumaric acid alkyl esters for suppressing host versus graft reaction |
| 03/19/2002 | US6358932 Antisense oligonucleotide inhibition of raf gene expression |
| 03/19/2002 | US6358931 Oligonucletide conjugated to imidazole; intercalation and coordination compounds; medical diagnosis, gene therapy; antisense agents |
| 03/19/2002 | US6358929 Use of a peptide preventing the intolerance reactions of the skin, in particular in cosmetic compositions |
| 03/19/2002 | US6358928 Treating respiratory system, rheumatic and genetic disorders |
| 03/19/2002 | US6358926 Neurotoxin therapy for inner ear disorders |
| 03/19/2002 | US6358925 Administering insulin-like growth factor |
| 03/19/2002 | US6358924 GLP-1 formulations |
| 03/19/2002 | US6358923 Preventing and diagnosing blood, genetic, and nervous system disorders associated with decreased genetic expression |
| 03/19/2002 | US6358921 Cyclic polypeptide with low hemolytic activity; killing fungi, mycoplama, grampositive and gramnegative bacteria; side effect reduction |
| 03/19/2002 | US6358920 Nonapeptide anticarcinogenic and antimetastasis agents |
| 03/19/2002 | US6358918 Administering heat treated, nitrosated proteins selected from albumin, orosomucoid, tissue plasminogen activator, fibrinogen, lys-plasminogen, and/or hemoglobin to humans to improve perfusion and microcirculation |
| 03/19/2002 | US6358917 Injection into depressor anguli oris muscle to cause paralysis; aging resistance |
| 03/19/2002 | US6358916 Biological activity of IGF-I E domain peptide |
| 03/19/2002 | US6358915 Administering uteroglobin as anticarcinogenic or antitumor agent to treat breast, lung or prostate cancer |
| 03/19/2002 | US6358741 Polynucleotide coding propagation regulator; for treating cell proliferative defects |
| 03/19/2002 | US6358738 Polo box therapeutic compositions, methods, and uses therefor |
| 03/19/2002 | US6358735 Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen |
| 03/19/2002 | US6358732 Nucleotide sequences preferential polypeptides for use in the treatment of defects in central nervous system |
| 03/19/2002 | US6358727 Nucleotide sequences coding binding protein for use in treatment and prevention of infections |
| 03/19/2002 | US6358725 Mouse aspartic secretase-1 (mASP1) |